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INTRODUCTION 
Non-ionic surfactant vesicles known as niosomes are 
microscopic lamellar structures formed on admixture of a 
non-ionic surfactant, cholesterol and dicetyl phosphate with 
subsequent hydration in aqueous media. Proniosomes offer a 
versatile vesicle drug delivery concept with potential for 
delivery of drugs via transdermal route. This would be 
possible because proniosomes form niosomes upon hydration 
with water from skin following topical application under 
occlusive conditions. Proniosomes minimizes problems of 
niosomes physical stability such as aggregation, fusion and 
leaking and provide additional convenience in transportation, 
storage and dosing. Transdermal therapeutic system has 
generated an interest as this system provides the considerable 
advantage of a non-invasive parenteral route for drug 
therapy, avoidance of first pass gut and hepatic metabolism, 
decreased side effects and relative ease of drug. Provesicular 
systems had attracted researchers as an alternate strategy for 
transdermal delivery of drugs because of the non-toxicity and 
penetration effect of lecithin/surfactants. Provesicular 
systems have been exploited in oral drug delivery in the form 
of tablets, beads or capsules and have shown improved 
dissolution and absorption characteristics.  
Based on the investigations provesicular systems appear to 
be an alternate drug carrier for various routes of drug 
administration. Flurbiprofen, are nonsteroidal anti-
inflammatory drug (NSAIDs) is used for the relief of pain 
and inflammation associated with rheumatoid arthritis and  
 
osteoarthritis.
1
 It exhibits anti-inflammatory, analgesic and 
antipyretic activities. It is also used in mild to moderated 
pain including dysmenorrheal and migraine. Flurbiprofen is 
more potent than Ibuprofen but has more gastric side effect 
like peptic ulceration and severe gastrointestinal bleeding 
may occurs. The plasma half life (t1/2) of flurbiprofen is 4-6 
hours. Hence repeated administration of high dose (100 mg: 
three time a day) is required for effective management of 
rheumatoid arthritis and osteoarthritis. It will be also affected 
through transdermal route because of its size, nature and 
chemistry, these systems give better drug permeability from 
biological bioavailability membranes and helps in 
solubilization of some practically insoluble drugs and hence 
solve problems of many drug.
2
 To overcome the problem like 
gastric side effect, short half life and low bioavailability etc 
of flurbiprofen can be solved by developing the formulation 
of flurbiprofen as proniosome gel. 
MATERIALS: 
Flurbiprofen was a gift from F.D.C. Mumbai, cholesterol, 
and dialysis tubing was purchased from Hi-Media 
Laboratories (Mumbai, India). Span 20, 40, 60, 80 and BRIJ 
35 were purchased from Central Drug House (Delhi, India). 
All other chemicals and solvents were of analytical grade and 
obtained from Central Drug House Delhi, India. 
 
 
ABSTRACT 
The purpose of this research is to design proniosomal gel drug delivery system of flurbiprofen in a trial to overcome the 
adverse effects associated with oral administration of the drug. This can be overcome by the use of vesicular drug delivery 
system. Encapsulation of a drug in vesicular structure can be predicted to prolong the existence of the drug in the systemic 
circulation and thus enhance penetration into target tissue and reduce toxicity. Due to the limited solvent system present, the 
proniosomes formed were the mixture of many phases of liquid crystal, viz. lamellar, hexagonal and cubic phase liquid 
crystals. The potential of proniosomes as a transdermal drug delivery system of flurbiprofen was investigated by encapsulating 
the drug in various formulations of proniosomal gel composed of various ratios of sorbitan fatty acid esters, cholesterol, 
prepared by coacervation-phase separation method. The formulated systems were characterized in vitro for size, vesicle count, 
drug entrapment, drug release profiles and vesicular stability at different storage conditions. Stability studies for proniosomal 
gel were carried out for 4 weeks. The method of proniosome loading resulted in an encapsulation yield of 30.6 – 75.4%. In-
vitro studies showed prolonged release of entrapped flurbiprofen. At refrigerated conditions, higher drug retention was 
observed. It is evident from this study that proniosomes are a promising prolonged delivery system for flurbiprofen and have 
reasonably good stability characteristics. 
Keywords: Proniosomes, flurbiprofen, In-vitro release, Transdermal delivery, Stability studies. 
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METHOD: 
Proniosomal gel was prepared by a coacervation-phase 
separation method. Precisely weighed amounts of surfactant, 
cholesterol and drug were taken in a clean and dry wide 
mouthed glass vial of 5.0 ml capacity and alcohol (0.5 ml) 
was added to it. All the ingredients were mixed well with a 
glass rod; the open end of the glass bottle was covered with a 
lid to prevent the loss of solvent from it and warmed over 
water bath at 60-70°C for about 5 min until the surfactant 
mixture was dissolved completely. Then the aqueous phase 
(0.1% glycerol solution) was added and warmed on a water 
bath till a clear solution was formed which was converted 
into proniosomal gel on cooling. The gel so obtained was 
preserved in the same glass bottle in dark conditions for 
characterization. Compositions of proniosomal gel 
formulations are given in Table1. 
CHARACTERIZATION OF PRONIOSOMAL GEL: 
Optical microscopic examination: 
Hydration of proniosomal gel (100mg) was done by adding 
saline solution (0.9% solution) in a small glass vial with 
occasional shaking for 10 min. The dispersion was observed 
under optical microscope at 100 x magnification. The sizes 
of 200-300 vesicles were measured using a calibrated ocular 
and stage micrometer (Erma, Tokyo) fitted in the optical 
microscope.
4
 
Entrapment efficiency 
To evaluate the loading capacity of proniosomal systems for 
flurbiprofen, proniosomal gel (100mg) was dispersed in 
distilled water and warmed a little for the formation of 
niosomes. Then the dispersion was centrifuged at 18000 rpm 
for 40min at 5ºC (Remi CPR-24 centrifuge). The clear 
fraction was used for the determination of free drug at 247.0 
nm spectrophotometrically. The percentage encapsulation 
efficiency was calculated from Equation 1... 
% Encapsulation Efficiency = [1- (Unencapsulated drug / 
Total drug)] x 100 
7, 9
 
In-Vitro Release  
The in vitro drug release studies of proniosomal gel were 
carried out by means of treated cellophane membrane. In-
vitro release studies on proniosomal gel were performed 
using locally Fabricated Franz-diffusion cell. The capacity of 
receptor compartment was 15 ml. The area of donor 
compartment exposed to receptor compartment was 
1.389cm
2
. The dialysis cellophane membrane 
(MMCO14KDC) was mounted between the donor and 
receptor compartment. A weighed amount of proniosomal 
gel was placed on one side of the membrane.  
The receptor medium was saline phosphate buffer pH 7.4. 
The receptor compartment was surrounded by a water jacket 
to maintain the temperature at 37±1
º
C. Heat was provided 
using a thermostatic hot plate with a magnetic stirrer.
7, 14
 The 
receptor fluid was stirred by a Teflon-coated magnetic bead 
fitted to a magnetic stirrer (Bio-Craft Scientific Systems Pvt. 
Ltd., Agra). At each sampling interval, (1 ml) were 
withdrawn and were replaced by equal volumes of fresh 
receptor fluid on each occasion. Samples withdrawn were 
analyzed spectrophotometrically (Shimadzu-1700) at 247 
nm. 
15
 
Stability Studies:  
The ability of vesicles to retain the drug (Drug Retention 
Behaviour) was assessed by keeping the proniosomal gel at 
three different temperature conditions, i.e., Refrigeration 
Temperature (4-8
0
C), Room Temperature (25±2
0
C) and oven 
(45±2
0
C). Throughout the study, proniosomal formulations 
were stored in aluminum foil-sealed glass vials. 
RESULTS AND DISCUSSION 
Proniosome gel containing flurbiprofen were prepared by 
Coacervation phase separation method. Formation of vesicle 
mainly depends on the concentration of cholesterol and 
surfactant ratio.Table1 show that the entrapment efficiency 
of different optimized formulation. The entrapment 
efficiency of flurbiprofen within the formulation  from 
40.6% for span 80 vesicle (SKJ4) to high as 82.56 % for Brij 
35 (SKK3) vesicle show higher entrapment efficiency for 
Brij 35 formulation can be attributed to its length of longer 
side chain, and it easily diffuse into receptor membrane 
integrity ,orientation and packaging ability. 
The entrapment efficiency of proniosomal gel was attributed 
due to the amphiphillic nature of the drug. The entrapment 
efficiency was found maximum for SKK3 formulation due to 
higher HLB value, of the formulation, which result in larger 
vesicle hence more entrapment of drug into the vesicle. The 
effect of cholesterol on flurbiprofen entrapment was varied 
according to the nonionic surfactant used, cholesterol was 
found to have little effect on the flurbiprofen entrapment. 
The results of analysis reports are shown in the (Table 2); it 
shows that vesicle size decrease with decrease in HLB value. 
Vesicle size decreases in the following manner span 20 > 
span 40 > span 60 > span 80 > Brij 35> span 80, i.e. higher 
the HLB value result in reduction in surface free energy 
which allow to form vesicle of larger and hence small area 
exposed to dissolution medium.
Table 1: Composition of proniosomal gel formulation 
F. Code Drug (mg) Span20 (mg) Span40 (mg) Span60 (mg) Span80 (mg) Brij35 (mg) CHL Solvent ratio (ml) 
SKG3 50 50 - - - - 50 0.5  
SKH3 50 - 50 - - - 50 0.5 
SKI3 50 - - 50 - - 50 0.5 
SKJ3 50 - - - 50 - 50 0.5 
SKK3 50 - - - - 50 50 0.5  
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Table: 2 various result of proniosomal gel formulation 
 
The proniosomal formulation having low cholesterol content 
was found to cause low entrapment efficiency, which might 
be because of leakage of vesicle. The higher entrapment may 
be explained by high cholesterol content (50 % of the total 
lipid) reported that entrapment efficiency increase with 
increasing cholesterol content. It was also observed that very 
high cholesterol content had a lowering effect on drug 
entrapment to the vesicle. This could be due to the fact that 
cholesterol beyond a certain level starts disrupting the regular 
bilayer structure leading to loss of drug entrapment. 
15
 
This result are also observed  and similar as study in the 
proniosomal formulation using Brij 35, span 60 and tween 80 
surfactant. In this prepare vesicle using Brij 35: cholesterol 
show better drug release in Comparision to other surfactant.
15 
Our finding results are observed similar as study in Brij 35, 
Brij 58, and Brij 92 Brij 52 etc. The conclusion of this study 
show that Brij 35 did not form niosome in the absence of 
cholesterol, but in the presence of cholesterol niosome 
formed and vesicle shows more stable and less leaky.
16
  
This result are also observed in a comparative study on the 
effect of some polyoxyethylene alkyl ether like (Brij 78, Brij 
92, Brij 72, Brij 52) and sorbitan fatty acid ester surfactants 
on the performance of transdermal proniosomal gel using 
experimental design. In this the Brij 52 show similar 
property as compare to Brij 35.The findings of this  study 
shows that the niosome formulation prepared with Brij 52 
was better drug release in Comparision to other Brij 
Component. 
 
 
Figure: 1 In-vitro drug release profile of selected 
proniosomal gel formulation 
 
 
 
Figure 2: Scanning electron microscopy of formulation 
SKT3                          
 
Figure 3: Transmission electron photomicrograph of SKT3 
 Most of the surfactant used to make non-ionic surfactant 
vesicle have low aqueous solubility, however freely soluble 
non-ionic surfactant such as Brij 35 can form micelles on 
hydration due to the presence of more polar head group in 
the chain, in the addition of cholesterol they abolish the more 
polar part present in surfactant mainly due to lipophillic in 
nature and help in formation of vesicle in the eqiumolar ratio 
of Brij 35 and cholesterol show better result (1:1). The 
proniosome formation takes place from Brij 35 with the 
presence of cholesterol, the length of alkyl chain show a 
crucial factor of permeability, Brij 35 have long lauryl(c12) 
chain, thus the long chain influence the HLB of the 
surfactant and also lead to the higher drug entrapment 
efficiency and also show better stability of the proniosome 
using Brij 35. Cholesterol is one of the most important 
additives included in the formulation in order to prepare 
stable niosome. Cholesterol stabilizes bilayer, prevents 
leakiness and retards permeation of solutes enclosed in the 
aqueous core of these vesicle which could be able to 
effectively prevent leakage of drug from niosome. 
Cholesterol is thus included in 1: 1 molar ratio (non-ionic 
surfactant: cholesterol), show better result in the case of Brij 
35. Thus it can be concluded that Brij 35 show highest drug 
release by the fact that niosome exhibit an alkyl chain length-
dependent drug release 
In-vitro drug release was carried out by locally fabricated 
Franz diffusion cell. The ability of ethanolic lipid vesicles 
called ethosomes to deliver flurbiprofen was investigated by 
determining the flux of flurbiprofen. The data of percent 
cumulative amount of flurbiprofen permeated per unit area 
across dialysis membrane via various formulations was 
given. The amount of drug released from different 
S. 
No. 
F. 
Code 
Vesicle size  
(nm) 
% Drug 
Entrapment  
% drug 
released 
1. SKG3 375.2 57.3±1.97 57.78±0.45 
2. SKH3 330.6 62.6±1.65 62.75±0.87 
3. SKI3 305.6 76.0±1.98 68.12±0.86 
4. SKJ3 265.4 57.3±1.63 74.85±0.56 
5. SKK3 315.6 82.56±1.55 80.42±0.67 
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proniosomal gel formulation was found in order of SKK3 > 
SKJ3 > SKI3 > SKH3 > SKG3. It was found that SKK3 
showed a controlled release property from 10-24 hrs. The 
result of cumulative % drug release 10
th
 hour was found to be 
45.12% & 80.42% at 24 hour .Thiss mins it show a better 
controlled property. The release profile was found constant 
between 10-24 hours. So the formulation was found to 
exhibit a zero order controlled release profile. Other 
formulation SKG3, SKH3, SKI3, SKJ3, also show good 
controlled release property. The in-vitro release of 
flurbiprofen proniosomal gel was limited by two barriers, 
namely phospholipids bilayer & dialysis membrane.  
The formulation SKK3 (50% Brij 35 and 50% cholesterol) 
showed highest amount of % drug released (80.42%). The 
enhanced % drug release obtained from the proniosomal gel 
system could be justified on the basis of dual function 
performed by ethanol present in the proniosomal 
formulations, length of side chain, i.e. fluidizing both the 
vesicular lipid bilayer and greater malleability to the vesicles 
and enhancing permeability of the skin. 
Overall, the data clearly indicate that the proniosomal gel 
formulation SKK3 (50% w/w cholesterol and 50% w/w Brij-
35) showed the highest entrapment efficiency (82.56 %), 
optimum size (315.6 nm), highest cumulative amount of % 
drug released (80.42%). Thus justifying itself as an 
optimized formulation and used for further skin in-vivo 
studies.   
Stability study 
In order to determine the percent drug remaining entrapped 
in vesicles and percent drug lost from Proniosome gel 
subjecting at temperature 4±2
o
C, 37±2
o
C and 45±2
o
C for 45 
days, were determined drug lost at time interval of 15 days. 
On the basis of entrapment efficiency and controlled release 
property, formulation SKK3 selected for the stability studies. 
Stability study was carried out in term of % drug leacked.  
Results showed that proniosomal gel formulation was quite 
stable at refrigeration and room temperature. In this 
condition not much leakage of drug was found at there 
temperature. Percent drug retained at 45ºC might have 
decreased due to the melting of surfactant and lipid present in 
the formulation to the proniosomal gel formulation can be 
stored at refrigeration and room temperature. Thus it can be 
concluded that the shelf life of proniosomal powder 
formulation is more than the proniosomal formulation. 
Because in dry surfactant can be avoided, by forming the 
suspension as needed, precipitation and aggregation can also 
be avoided. 
CONCLUSION 
Thus from above study it can be concluded that the 
proniosomes gel posses higher entrapment efficiency and 
utilizes alcohol, which itself act as penetration enhancer. The 
elicited an increase of the percutaneous permeation of 
flurbiprofen in-vitro and. In addition, In-vitro experiments 
showed that flurbiprofen proniosomes gel can ensure a 
sustained release of the drug and hence a prolongation of its 
therapeutic activity, which can be related to an accumulation 
of flurbiprofen in the skin. 
These findings are very encouraging and confirm that 
proniosomes are a very promising carrier for the topical 
administration due to the enhanced delivery of drugs through 
the skin thus prompting various opportunities for the 
development of suitable therapeutic strategies through the 
topical route. The formulation is easy to scale up as the 
procedure is simple and do not involve lengthy procedure 
and unnecessary use of pharmaceutically unacceptable 
additives.  It offers direct fabrication of transdermal patch 
and do not require dispersion of vehicle into polymer matrix. 
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